# Ex Vivo Perfusion of Gene-Edited Porcine Livers in Patients With Severe Hepatic Failure

> **NCT07519005** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Xijing Hospital** · enrollment: 1 (actual)

## Conditions studied

- Hepatic Failure

## Interventions

- **BIOLOGICAL:** Ex vivo perfusion of six-gene-edited porcine liver
- **DRUG:** Multi-drug immunosuppressive therapy

## Key facts

- **NCT ID:** NCT07519005
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-01-31
- **Primary completion:** 2026-02-03
- **Final completion:** 2026-12-31
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07519005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07519005, "Ex Vivo Perfusion of Gene-Edited Porcine Livers in Patients With Severe Hepatic Failure". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07519005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*